论文部分内容阅读
到年报批露完为止,在深沪两市挂牌的经营酒类的公司共18家,其中成都华联和四川制药是于1999年通过资本运作跨入到酒类板块中来的。四川郎酒集团斥资近600O万控股成都华联,成为其第一大股东。欲借助华联在全国的销售网络优势拓展郎酒的销售市场,从而使成都华联形成酒业、百货业双管齐下,携手开拓新产业的格局。而四川制药则是通过资产置换和等价受让的形式控股全兴酒业有限公司51.12％的股权。使自己的经营范围从制药扩展到酒类产品的生产和销售领域。这是国家限制发展酿酒产业,酒类企业运用资本市场进行调整和发展的一种有益尝试。由于上述两家是于1999年开始进入酿酒领域的。因此,在下面的年报分析中不涉及这两家公司的业绩评述。从酒类公司的年报来看,1998年初的山西假酒案,给整个白酒行业以沉重打击。同时,由于酒类公司从1998年
By the end of the annual report, there were a total of 18 wine companies listed in Shenzhen and Shanghai, among which Chengdu Hualian and Sichuan Pharmaceuticals entered into the wine sector in 1999 through capital operations. Sichuan Langjiu Group invested nearly 600 million in Chengdu Hualian, becoming its largest shareholder. Want to use Hualian’s sales network in the country’s sales network to expand Langmusu’s sales market, which will enable Chengdu Hualian to form a two-pronged approach to wine and department stores, and jointly develop new industries. Sichuan Pharmaceuticals, on the other hand, controls 51.12% of Quanxing Wine Co., Ltd. in the form of asset replacement and equivalent transfer. To expand its business scope from pharmaceuticals to the production and sales of alcoholic products. This is a useful attempt by the state to restrict the development of the wine industry and alcohol companies to use the capital market for adjustment and development. Since the above two were started in 1999 into the winemaking field. Therefore, the performance review of the two companies is not involved in the following annual report analysis. According to the annual report of the liquor company, the case of Shanxi fake wine in early 1998 severely hit the entire liquor industry. At the same time, as alcohol companies from 1998